Free Newsletter
Solvay shelves obesity drug
Solvay took a hard look at its experimental obesity drug and decided that the regulatory hurdles it faces are simply too high. The data for SLV319--in Phase II--"confirmed its clinical activity and its efficacy," according to the company. But the developer opted to shelve its work on the program nevertheless. Release | Report
Comments (1) | Post a comment
Comments
By Anonymous | Posted 3:45pm | November 18, 2008
Dang! As an intern at BMS I reduced the processing time on this from about two days to less than 15 hours. I was hoping that it would make it to market.
